[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335620-105":59,"doc-detail-335620-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","dual-multivalent-aptamer-based-drug-delivery-platform-for-targeted-src-silencing-to-enhance-doxorubicin-sensitivity-in-endometrial-cancer","Dual-Multivalent Aptamer-Based Drug Delivery Platform for Targeted SRC Silencing to Enhance Doxorubicin Sensitivity in Endometrial Cancer","","Endometrial cancer threatens women’s health, and doxorubicin remains a key chemotherapy drug whose benefit is often limited by low sensitivity. The study demonstrates that SRC regulates endometrial cancer responsiveness to doxorubicin and builds a targeted silencing drug delivery platform. The platform combines rolling circle amplification with dual-multivalent aptamers to deliver therapeutics directly to tumor cells, improving genetic-level drug responsiveness. Results in cellular and animal models suggest enhanced susceptibility to ferroptosis and improved precision treatment potential.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/dual-multivalent-aptamer-based-drug-delivery-platform-for-targeted-src-silencing-to-enhance-doxorubicin-sensitivity-in-endometrial-cancer/335620/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/dual-multivalent-aptamer-based-drug-delivery-platform-for-targeted-src-silencing-to-enhance-doxorubicin-sensitivity-in-endometrial-cancer/335620.png","ImageObject",300,407,{"name":92,"@type":93},"Clementine","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address in endometrial cancer chemotherapy?","Question",{"text":112,"@type":113},"Low sensitivity limits the effectiveness of doxorubicin in advanced and recurrent endometrial cancer, reducing therapeutic impact despite its common use.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the proposed platform deliver and silence targeted components?",{"text":117,"@type":113},"It uses rolling circle amplification and dual-multivalent aptamers to precisely deliver therapeutics to tumor cells while enabling targeted SRC silencing.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports the platform’s effectiveness and potential mechanism?",{"text":121,"@type":113},"The platform improves doxorubicin sensitivity at the genetic level and is validated in cellular and animal models, suggesting increased cancer susceptibility to ferroptosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335620,1790131466,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":4},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","Ivyspring  \nInternational Publisher  \nInternationalJournal of Biological Sciences  \n2024; 20(15): 5812-5830. doi: 10.7150/ijbs.101059  \nResearch Paper  \nDual-Multivalent Aptamer-Based Drug Delivery Platform for Targeted SRC Silencing to Enhance Doxorubicin Sensitivity in Endometrial Cancer  \nHaojia Li1\\#, Shuangshuang Cheng1\\#, Qi Zhang1, Ting Zhou1, Tangansu Zhang1, Shuangge Liu1, Yingying Peng1, Jia Yu1, Jingwen Xu3, Qi Wang4, Jun Zhang1, Yuwei Yao1,􀀍, Hongbo Wang1,2,􀀍  \n1. Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430023, China.  \n2. Clinical Research Center of Cancer Immunotherapy, Wuhan 430023, China.  \n3. School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.  \n4. Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430023, China.  \n\\# Haojia Li and Shuangshuang Cheng contributed equally to this work.  \n􀀍 Corresponding authors: Yuwei Yao-Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430023, China; Email: [1160603775@qq.com.](1160603775@qq.com. Hongbo Wang-Department of Obstetrics and Gynecology)[ Hongbo Wang-](1160603775@qq.com. Hongbo Wang-Department of Obstetrics and Gynecology)[Department of Obstetrics and Gynecology](1160603775@qq.com. Hongbo Wang-Department of Obstetrics and Gynecology), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430023, China; Clinical Research Center of Cancer Immunotherapy, Wuhan 430023, China; [Email: hb_wang1969@sina.com](Email: hb_wang1969@sina.com).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2024.07.17; Accepted: 2024.10.19; Published: 2024.10.28  \nAbstract  \nEndometrial cancer poses a significant threat to women's health. Doxorubicin is commonly used in chemotherapy for advanced and recurrent cases; however, low sensitivity frequently limits its effectiveness. In this study, we verified that SRC modulates the sensitivity of endometrial cancer to chemotherapy of doxorubicin and developed a targeted silencing drug delivery platform that employs rolling circle amplification and dual-multivalent aptamers to precisely deliver therapeutics directly to tumor cells. This platform enhanced endometrial cancer cell sensitivity to doxorubicin by modulating drug responsiveness at the genetic level. Our results suggest that this approach may improve cancer cell susceptibility to ferroptosis. The efficacy and safety of this platform were validated in both cellular and animal models. This study provides a new solution for realizing the precision treatment of endometrial cancer and lays a theoretical foundation for exploring the mechanism of endometrial cancer.  \nKeywords: endometrial cancer, targeted drug delivery, doxorubicin, rolling circle amplification, ferroptosis  \nIntroduction  \nEndometrial cancer (EC) has the highest global incidence among the three gynecological malignancies[1] . Its prevalence and mortality are persistently increasing[2] . In 2023, the International Federation of Gynecology and Obstetrics defined four molecular subtypes of EC based on The Cancer Genome Atlas (TCGA): DNA polymerase epsilon (POLE) ultramutated, microsatellite instability/high mismatch repair deficiency (MSI-H/dMMR), copy-number low (CNL), and copy-number high (CNH)[3] . These classifications mitigate the constraints of the previous Bokhman classification system. Although patients with early-stage EC have a  \nfavorable 5-year survival rate exceeding 80%, those with advanced EC face shorten","cbCaiq5Bjea8b1jH","https://ap.wps.com/l/cbCaiq5Bjea8b1jH","pdf",7624660,"English","# Abstract\n# Introduction\n## Endometrial cancer background and molecular subtypes\n## Chemotherapy context and doxorubicin mechanisms\n## Challenges: resistance and the rationale for targeted approaches","[{\"question\":\"What problem does the study address in endometrial cancer chemotherapy?\",\"answer\":\"Low sensitivity limits the effectiveness of doxorubicin in advanced and recurrent endometrial cancer, reducing therapeutic impact despite its common use.\"},{\"question\":\"How does the proposed platform deliver and silence targeted components?\",\"answer\":\"It uses rolling circle amplification and dual-multivalent aptamers to precisely deliver therapeutics to tumor cells while enabling targeted SRC silencing.\"},{\"question\":\"What evidence supports the platform’s effectiveness and potential mechanism?\",\"answer\":\"The platform improves doxorubicin sensitivity at the genetic level and is validated in cellular and animal models, suggesting increased cancer susceptibility to ferroptosis.\"}]","Dual-Multivalent Aptamer-Based Drug Delivery Platform for Targeted SRC Silencing to Enhance Doxorubicin Sensitivity in Endometrial Cancer | PDF",1790011665,48]